Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054457 · ClinicalTrials.gov registry record · Phase 2
Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
A Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 20
- Study locations
NCT00054457: Completed Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Alliance for Clinical Trials in Oncology.
NCT00054457 is a Phase 2 study of Gastric Cancer and Esophageal Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 46 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00054457, a Phase 2 study of Gastric Cancer and Esophageal Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study of the effectiveness of combining docetaxel with capecitabine in treating patients who have metastatic cancer of the stomach or gastroesophageal junction.
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG capecitabine
Study Locations (20)
Kansas
- Cancer Center of Kansas, PA - Chanute - Chanute
- Cancer Center of Kansas, PA - Dodge City - Dodge City
- Cancer Center of Kansas, PA - El Dorado - El Dorado
- Cancer Center of Kansas, PA - Kingman - Kingman
- Southwest Medical Center - Liberal
- Cancer Center of Kansas, PA - Newton - Newton
- Cancer Center of Kansas, PA - Parsons - Parsons
- Cancer Center of Kansas, PA - Pratt - Pratt
- Cancer Center of Kansas, PA - Salina - Salina
- Cancer Center of Kansas, PA - Wellington - Wellington
- Associates in Womens Health, PA - North Review - Wichita
- Cancer Center of Kansas, PA - Medical Arts Tower - Wichita
- Cancer Center of Kansas, PA - Wichita - Wichita
- CCOP - Wichita - Wichita
- Via Christi Cancer Center at Via Christi Regional Medical Center - Wichita
- Cancer Center of Kansas, PA - Winfield - Winfield
Minnesota
- Fairview Ridges Hospital - Burnsville
- Mercy and Unity Cancer Center at Mercy Hospital - Coon Rapids
- Fairview Southdale Hospital - Edina
- Mercy and Unity Cancer Center at Unity Hospital - Fridley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2003-09 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
What the finished NCT00054457 record still lists
NCT00054457 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.
NCT00054457 names 20 study sites across 2 states, led by Kansas, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00054457 about?
NCT00054457 is a clinical study titled "Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study of the effectiveness of combining docetaxel with capecitabine in treating patients who hav...
What is the current status of trial NCT00054457?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2003-09. Estimated completion is 2008-02.
What conditions does trial NCT00054457 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT00054457?
The interventions under investigation include: docetaxel (DRUG), capecitabine (DRUG).
Who is sponsoring clinical trial NCT00054457?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00054457 being conducted?
This trial has 20 study locations across Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00054457's enrollment target sits among peer trials
46 123rd of 153 higher than 31 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia